Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Amirah Etchegaray, Sanjivan Mudaliar, Kimberley Ryan, Karen Hay, Jason Hwang, Benedict Devereaux, Mark Appleyard, Florian Grimpen
{"title":"Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study","authors":"Amirah Etchegaray,&nbsp;Sanjivan Mudaliar,&nbsp;Kimberley Ryan,&nbsp;Karen Hay,&nbsp;Jason Hwang,&nbsp;Benedict Devereaux,&nbsp;Mark Appleyard,&nbsp;Florian Grimpen","doi":"10.1111/imj.16652","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Increasing numbers of older patients with pancreatobiliary disease are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Older patients may be at higher risk of ERCP-related adverse events due to their age and comorbidities; however, data are sparse.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This study aimed to evaluate long-term mortality, procedural outcomes and safety of ERCP in nonagenarians.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively evaluated consecutive patients aged ≥90 years who underwent ERCP at a tertiary hospital over 12 years. The primary outcome was survival. Secondary outcomes included procedural success and adverse events. Logistic regression was used to analyse procedural outcomes, and factors predictive of survival were identified using a Cox proportional hazard model visualised by Kaplan–Meier plot.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 159 consecutive ERCPs were performed in 115 nonagenarian patients. The mean age of the cohort was 92.3 (standard deviation ± 2.1) years. Choledocholithiasis (78.6%) was the most common indication, followed by malignant biliary obstruction (MBO, 18.9%) and bile leak (2.5%). Survival following ERCP for MBO at 30 days, 3 months and 1 year was 78%, 52% and 9%, respectively, compared to 98%, 94% and 89% for choledocholithiasis (<i>P</i> &lt; 0.001). Procedural success was achieved in 91% of ERCPs (benign or malignant). ERCPs performed for MBO were more likely to fail (<i>P</i> &lt; 0.001). Adverse events occurred in 5% of procedures.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Therapeutic ERCP in select nonagenarians is a clinically relevant intervention for both malignant and benign pathology. Age does not constitute a barrier to the performance of ERCP in appropriately selected patients. Nonagenarians may be counselled for a success and adverse event rate equivocal to younger populations.</p>\n </section>\n </div>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"55 3","pages":"435-443"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16652","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Increasing numbers of older patients with pancreatobiliary disease are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Older patients may be at higher risk of ERCP-related adverse events due to their age and comorbidities; however, data are sparse.

Aims

This study aimed to evaluate long-term mortality, procedural outcomes and safety of ERCP in nonagenarians.

Methods

We retrospectively evaluated consecutive patients aged ≥90 years who underwent ERCP at a tertiary hospital over 12 years. The primary outcome was survival. Secondary outcomes included procedural success and adverse events. Logistic regression was used to analyse procedural outcomes, and factors predictive of survival were identified using a Cox proportional hazard model visualised by Kaplan–Meier plot.

Results

A total of 159 consecutive ERCPs were performed in 115 nonagenarian patients. The mean age of the cohort was 92.3 (standard deviation ± 2.1) years. Choledocholithiasis (78.6%) was the most common indication, followed by malignant biliary obstruction (MBO, 18.9%) and bile leak (2.5%). Survival following ERCP for MBO at 30 days, 3 months and 1 year was 78%, 52% and 9%, respectively, compared to 98%, 94% and 89% for choledocholithiasis (P < 0.001). Procedural success was achieved in 91% of ERCPs (benign or malignant). ERCPs performed for MBO were more likely to fail (P < 0.001). Adverse events occurred in 5% of procedures.

Conclusion

Therapeutic ERCP in select nonagenarians is a clinically relevant intervention for both malignant and benign pathology. Age does not constitute a barrier to the performance of ERCP in appropriately selected patients. Nonagenarians may be counselled for a success and adverse event rate equivocal to younger populations.

安全性、有效性和内窥镜逆行胆管造影后的生存率:一项回顾性队列研究。
背景:越来越多的老年胰胆管疾病患者正在接受内镜逆行胆管造影(ERCP)。由于年龄和合并症,老年患者发生ercp相关不良事件的风险更高;然而,数据是稀疏的。目的:本研究旨在评估ERCP在老年患者中的长期死亡率、手术结果和安全性。方法:回顾性评价年龄≥90岁、在三级医院连续12年接受ERCP治疗的患者。主要结局是生存。次要结局包括手术成功和不良事件。采用Logistic回归分析程序结果,并采用Kaplan-Meier图可视化的Cox比例风险模型确定预测生存的因素。结果:115例老年患者共接受了159例ercp。队列的平均年龄为92.3岁(标准差±2.1)岁。最常见的指征是胆总管结石(78.6%),其次是恶性胆道梗阻(MBO, 18.9%)和胆漏(2.5%)。MBO患者在30天、3个月和1年的ERCP生存率分别为78%、52%和9%,而胆总管结石患者的生存率分别为98%、94%和89% (P结论:治疗性ERCP对部分老年患者的恶性和良性病理均有临床意义。在适当选择的患者中,年龄不构成ERCP的障碍。对于成功率和不良事件发生率与年轻人群不一致的情况,可能会向90多岁的老年人进行咨询。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信